Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant ...

Results exceeded all guided metrics Fourth quarter subscription ARR grew 34% year-over-year to $1.46 billion Fourth quarter revenue grew 46% year-over-year to $377.7 million 2,805 customers with $100K ...